On Tuesday, Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) was -5.14% drop from the session before settling in for the closing price of $7.59. A 52-week range for AUPH has been $4.71 – $10.67.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 3182.04% over the past five years. When this article was written, the company’s average yearly earnings per share was at 1015.00%. With a float of $122.12 million, this company’s outstanding shares have now reached $140.88 million.
Let’s look at the performance matrix of the company that is accounted for 130 employees. In terms of profitability, gross margin is 87.99%, operating margin of -0.57%, and the pretax margin is 3.17%.
Aurinia Pharmaceuticals Inc (AUPH) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Aurinia Pharmaceuticals Inc stocks. The insider ownership of Aurinia Pharmaceuticals Inc is 11.08%, while institutional ownership is 42.25%. The most recent insider transaction that took place on Mar 07 ’25, was worth 68,350. In this transaction Chief Medical Officer of this company sold 8,305 shares at a rate of $8.23, taking the stock ownership to the 153,484 shares. Before that another transaction happened on Mar 03 ’25, when Company’s Chief Executive Officer sold 195,593 for $8.00, making the entire transaction worth $1,564,744. This insider now owns 1,953,892 shares in total.
Aurinia Pharmaceuticals Inc (AUPH) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.11 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 1015.00% per share during the next fiscal year.
Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) Trading Performance Indicators
You can see what Aurinia Pharmaceuticals Inc (AUPH) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 4.17. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.21. Likewise, its price to free cash flow for the trailing twelve months is 22.88.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.04, a number that is poised to hit 0.10 in the next quarter and is forecasted to reach 0.75 in one year’s time.
Technical Analysis of Aurinia Pharmaceuticals Inc (AUPH)
Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) saw its 5-day average volume 1.67 million, a positive change from its year-to-date volume of 1.46 million. As of the previous 9 days, the stock’s Stochastic %D was 14.60%. Additionally, its Average True Range was 0.36.
During the past 100 days, Aurinia Pharmaceuticals Inc’s (AUPH) raw stochastic average was set at 15.78%, which indicates a significant increase from 8.93% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 31.62% in the past 14 days, which was lower than the 44.01% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $8.08, while its 200-day Moving Average is $7.43. Nevertheless, the first resistance level for the watch stands at $7.65 in the near term. At $8.10, the stock is likely to face the second major resistance level. The third major resistance level sits at $8.40. If the price goes on to break the first support level at $6.90, it is likely to go to the next support level at $6.60. Assuming the price breaks the second support level, the third support level stands at $6.15.
Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) Key Stats
There are 137,339K outstanding shares of the company, which has a market capitalization of 988.84 million. As of now, sales total 235,130 K while income totals 5,750 K. Its latest quarter income was 59,870 K while its last quarter net income were 1,430 K.
